Baidu
map

从中医药引子的神奇功效,谈患者依从性管理的重要价值

2017-07-17 Dr.2,MediCool医库董事长 新浪医药新闻

关于中医的有效性和科学性一直以来都存在很大的争议,在日常生活和临床学术等各个方面都有不同的说法。


关于中医的有效性和科学性一直以来都存在很大的争议,在日常生活和临床学术等各个方面都有不同的说法。

本人对中医里一些玄之又玄的东西并不十分感冒,但某天我跟一位研究中医多年的资深业内人士交流后,突然有了一些新的感悟。

我当时和这位业内人士闲聊说到,很多中医的药引子例如什么5月份的没有破蛹的蝉,或者9月份某个山上的草药,或者清晨的露,这些药引子到底有什么真实的功效?与普通的材料有什么区别?到底有没有科学道理呢?

这位业内人士则向我举了另一个例子来类比,说是有一位中医看完某患者后,要求他要么每个月主动来看一次医生,要么医生每月飞过去给患者上门做诊疗,如果患者不同意的话就不治。

其实这么做的成本非常高,最后这个土豪患者接受了该中医的要求,并且在经过坚持不懈的复诊与中药治疗后,一年左右症状就大幅度改善直至消失。

从中医上来说,疾病要辩证看待,因为每个疾病都有很多表象或者深层的原因,开始的时候用药可能要温和扶正,后面也许需要以毒攻毒,或者再配合一系列的序贯治疗。

如此一来,就要求患者必须要坚持足够长的时间进行治疗,医生需要对患者依从性进行管理,如果坚持不到足够长的时间,或者只做了第一个阶段的治疗没有深入向下,那就无法获得预期的效果。

其实这都是通过非常“仪式化”的形式来推进患者依从性管理。从药引子来说,只那么一点点量,某月某地的某些奇奇怪怪的东西,其功效上是否真的相差这么大呢?可能并不是!

但是你获得药引子的过程会很艰难,限制条件很多,而且相对成本很高,因此当你付出很高的代价后,就会自然而然地坚持治疗,这是人性。

在坚持完整治疗疗程的同时,又必然改变了生活方式,比如戒烟戒酒不熬夜,同时又给了患者信念,花费了很多代价后一定会有好结果出现。三管齐下,非常好的疗效真的就诞生了。

其实无论中医还是西医,患者依从性管理都是非常重要的。患者需要坚持疗程,这并不是为了卖药的说话,也不是因为医生处方有回扣,这里的核心是推进患者依从性管理,能够真实让患者获益,能够降低医疗总成本,避免随意断药而导致的病情反复,降低并发症的发生,有效改善生活质量。

移动医疗在患者依从性管理和医患沟通方面会发挥巨大的作用。

有多方数据证明在移动医疗工具进入患者随访领域后,当医生可以与患者在线上进行有效沟通时,患者依从性会大幅上升。

特别是在现在诊疗费普遍大幅上升的前提下,北上广的挂号费从十几二十块涨到了25,50,100元,经济杠杆驱动会导致患者看门诊的次数下降,依从性会下降,但是药品获得方式会越来越方便。

那么用移动医疗的方式进行复诊续方与随访,配合医药电商和附近药店购药以及DTP送药上门后,能够更低成本提高患者依从性。

移动医疗不断与健康险,重疾险和税优相结合,占领新的就医与获取医疗信息入口,特别是在慢病随访,手术康复与重大疾病领域,将会发挥出巨大的价值。

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (7)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1811277, encodeId=91aa18112e7ee, content=<a href='/topic/show?id=f0638e57816' target=_blank style='color:#2F92EE;'>#药引子#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87578, encryptionId=f0638e57816, topicName=药引子)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=951d2500061, createdName=12498717m66(暂无昵称), createdTime=Wed Jun 06 18:24:00 CST 2018, time=2018-06-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=224752, encodeId=ef22224e5239, content=不错的文章不错的文章, beContent=null, objectType=article, channel=null, level=null, likeNumber=96, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=eff51996281, createdName=1e1b8538m79(暂无匿称), createdTime=Fri Jul 21 21:27:23 CST 2017, time=2017-07-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1319290, encodeId=f7c71319290ae, content=<a href='/topic/show?id=60172686668' target=_blank style='color:#2F92EE;'>#依从性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=26866, encryptionId=60172686668, topicName=依从性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c9df476, createdName=fyxzlh, createdTime=Wed Jul 19 03:24:00 CST 2017, time=2017-07-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1408991, encodeId=6fa4140899112, content=<a href='/topic/show?id=2c1c35262a9' target=_blank style='color:#2F92EE;'>#医药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=35262, encryptionId=2c1c35262a9, topicName=医药)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=36f62754598, createdName=cathymary, createdTime=Wed Jul 19 03:24:00 CST 2017, time=2017-07-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=223235, encodeId=aa092232352d, content=中医博大精深, beContent=null, objectType=article, channel=null, level=null, likeNumber=89, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/05/25/aee510ed68ce4736e9fe4ec7d03c01b1.jpg, createdBy=ce892064652, createdName=楠博One, createdTime=Mon Jul 17 14:34:19 CST 2017, time=2017-07-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=223230, encodeId=24fb2232308e, content=谢谢分享,学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=102, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo6Nx0VGA4QMDzOP8oAgnV4h51EjSfehJ9QxyiaSmw8PB56BhY8KXFSxHCibXrzcy4abrzSibXQPxJ9kzrLcJyhhB8a/0, createdBy=1d3b1672603, createdName=明月清辉, createdTime=Mon Jul 17 14:14:56 CST 2017, time=2017-07-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=223206, encodeId=27c222320690, content=学习了,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=115, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=550d2008262, createdName=luominglian113, createdTime=Mon Jul 17 12:58:53 CST 2017, time=2017-07-17, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1811277, encodeId=91aa18112e7ee, content=<a href='/topic/show?id=f0638e57816' target=_blank style='color:#2F92EE;'>#药引子#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87578, encryptionId=f0638e57816, topicName=药引子)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=951d2500061, createdName=12498717m66(暂无昵称), createdTime=Wed Jun 06 18:24:00 CST 2018, time=2018-06-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=224752, encodeId=ef22224e5239, content=不错的文章不错的文章, beContent=null, objectType=article, channel=null, level=null, likeNumber=96, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=eff51996281, createdName=1e1b8538m79(暂无匿称), createdTime=Fri Jul 21 21:27:23 CST 2017, time=2017-07-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1319290, encodeId=f7c71319290ae, content=<a href='/topic/show?id=60172686668' target=_blank style='color:#2F92EE;'>#依从性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=26866, encryptionId=60172686668, topicName=依从性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c9df476, createdName=fyxzlh, createdTime=Wed Jul 19 03:24:00 CST 2017, time=2017-07-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1408991, encodeId=6fa4140899112, content=<a href='/topic/show?id=2c1c35262a9' target=_blank style='color:#2F92EE;'>#医药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=35262, encryptionId=2c1c35262a9, topicName=医药)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=36f62754598, createdName=cathymary, createdTime=Wed Jul 19 03:24:00 CST 2017, time=2017-07-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=223235, encodeId=aa092232352d, content=中医博大精深, beContent=null, objectType=article, channel=null, level=null, likeNumber=89, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/05/25/aee510ed68ce4736e9fe4ec7d03c01b1.jpg, createdBy=ce892064652, createdName=楠博One, createdTime=Mon Jul 17 14:34:19 CST 2017, time=2017-07-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=223230, encodeId=24fb2232308e, content=谢谢分享,学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=102, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo6Nx0VGA4QMDzOP8oAgnV4h51EjSfehJ9QxyiaSmw8PB56BhY8KXFSxHCibXrzcy4abrzSibXQPxJ9kzrLcJyhhB8a/0, createdBy=1d3b1672603, createdName=明月清辉, createdTime=Mon Jul 17 14:14:56 CST 2017, time=2017-07-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=223206, encodeId=27c222320690, content=学习了,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=115, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=550d2008262, createdName=luominglian113, createdTime=Mon Jul 17 12:58:53 CST 2017, time=2017-07-17, status=1, ipAttribution=)]
    2017-07-21 1e1b8538m79(暂无匿称)

    不错的文章不错的文章

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1811277, encodeId=91aa18112e7ee, content=<a href='/topic/show?id=f0638e57816' target=_blank style='color:#2F92EE;'>#药引子#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87578, encryptionId=f0638e57816, topicName=药引子)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=951d2500061, createdName=12498717m66(暂无昵称), createdTime=Wed Jun 06 18:24:00 CST 2018, time=2018-06-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=224752, encodeId=ef22224e5239, content=不错的文章不错的文章, beContent=null, objectType=article, channel=null, level=null, likeNumber=96, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=eff51996281, createdName=1e1b8538m79(暂无匿称), createdTime=Fri Jul 21 21:27:23 CST 2017, time=2017-07-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1319290, encodeId=f7c71319290ae, content=<a href='/topic/show?id=60172686668' target=_blank style='color:#2F92EE;'>#依从性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=26866, encryptionId=60172686668, topicName=依从性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c9df476, createdName=fyxzlh, createdTime=Wed Jul 19 03:24:00 CST 2017, time=2017-07-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1408991, encodeId=6fa4140899112, content=<a href='/topic/show?id=2c1c35262a9' target=_blank style='color:#2F92EE;'>#医药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=35262, encryptionId=2c1c35262a9, topicName=医药)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=36f62754598, createdName=cathymary, createdTime=Wed Jul 19 03:24:00 CST 2017, time=2017-07-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=223235, encodeId=aa092232352d, content=中医博大精深, beContent=null, objectType=article, channel=null, level=null, likeNumber=89, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/05/25/aee510ed68ce4736e9fe4ec7d03c01b1.jpg, createdBy=ce892064652, createdName=楠博One, createdTime=Mon Jul 17 14:34:19 CST 2017, time=2017-07-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=223230, encodeId=24fb2232308e, content=谢谢分享,学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=102, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo6Nx0VGA4QMDzOP8oAgnV4h51EjSfehJ9QxyiaSmw8PB56BhY8KXFSxHCibXrzcy4abrzSibXQPxJ9kzrLcJyhhB8a/0, createdBy=1d3b1672603, createdName=明月清辉, createdTime=Mon Jul 17 14:14:56 CST 2017, time=2017-07-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=223206, encodeId=27c222320690, content=学习了,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=115, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=550d2008262, createdName=luominglian113, createdTime=Mon Jul 17 12:58:53 CST 2017, time=2017-07-17, status=1, ipAttribution=)]
    2017-07-19 fyxzlh
  4. [GetPortalCommentsPageByObjectIdResponse(id=1811277, encodeId=91aa18112e7ee, content=<a href='/topic/show?id=f0638e57816' target=_blank style='color:#2F92EE;'>#药引子#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87578, encryptionId=f0638e57816, topicName=药引子)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=951d2500061, createdName=12498717m66(暂无昵称), createdTime=Wed Jun 06 18:24:00 CST 2018, time=2018-06-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=224752, encodeId=ef22224e5239, content=不错的文章不错的文章, beContent=null, objectType=article, channel=null, level=null, likeNumber=96, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=eff51996281, createdName=1e1b8538m79(暂无匿称), createdTime=Fri Jul 21 21:27:23 CST 2017, time=2017-07-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1319290, encodeId=f7c71319290ae, content=<a href='/topic/show?id=60172686668' target=_blank style='color:#2F92EE;'>#依从性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=26866, encryptionId=60172686668, topicName=依从性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c9df476, createdName=fyxzlh, createdTime=Wed Jul 19 03:24:00 CST 2017, time=2017-07-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1408991, encodeId=6fa4140899112, content=<a href='/topic/show?id=2c1c35262a9' target=_blank style='color:#2F92EE;'>#医药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=35262, encryptionId=2c1c35262a9, topicName=医药)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=36f62754598, createdName=cathymary, createdTime=Wed Jul 19 03:24:00 CST 2017, time=2017-07-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=223235, encodeId=aa092232352d, content=中医博大精深, beContent=null, objectType=article, channel=null, level=null, likeNumber=89, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/05/25/aee510ed68ce4736e9fe4ec7d03c01b1.jpg, createdBy=ce892064652, createdName=楠博One, createdTime=Mon Jul 17 14:34:19 CST 2017, time=2017-07-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=223230, encodeId=24fb2232308e, content=谢谢分享,学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=102, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo6Nx0VGA4QMDzOP8oAgnV4h51EjSfehJ9QxyiaSmw8PB56BhY8KXFSxHCibXrzcy4abrzSibXQPxJ9kzrLcJyhhB8a/0, createdBy=1d3b1672603, createdName=明月清辉, createdTime=Mon Jul 17 14:14:56 CST 2017, time=2017-07-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=223206, encodeId=27c222320690, content=学习了,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=115, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=550d2008262, createdName=luominglian113, createdTime=Mon Jul 17 12:58:53 CST 2017, time=2017-07-17, status=1, ipAttribution=)]
    2017-07-19 cathymary
  5. [GetPortalCommentsPageByObjectIdResponse(id=1811277, encodeId=91aa18112e7ee, content=<a href='/topic/show?id=f0638e57816' target=_blank style='color:#2F92EE;'>#药引子#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87578, encryptionId=f0638e57816, topicName=药引子)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=951d2500061, createdName=12498717m66(暂无昵称), createdTime=Wed Jun 06 18:24:00 CST 2018, time=2018-06-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=224752, encodeId=ef22224e5239, content=不错的文章不错的文章, beContent=null, objectType=article, channel=null, level=null, likeNumber=96, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=eff51996281, createdName=1e1b8538m79(暂无匿称), createdTime=Fri Jul 21 21:27:23 CST 2017, time=2017-07-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1319290, encodeId=f7c71319290ae, content=<a href='/topic/show?id=60172686668' target=_blank style='color:#2F92EE;'>#依从性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=26866, encryptionId=60172686668, topicName=依从性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c9df476, createdName=fyxzlh, createdTime=Wed Jul 19 03:24:00 CST 2017, time=2017-07-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1408991, encodeId=6fa4140899112, content=<a href='/topic/show?id=2c1c35262a9' target=_blank style='color:#2F92EE;'>#医药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=35262, encryptionId=2c1c35262a9, topicName=医药)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=36f62754598, createdName=cathymary, createdTime=Wed Jul 19 03:24:00 CST 2017, time=2017-07-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=223235, encodeId=aa092232352d, content=中医博大精深, beContent=null, objectType=article, channel=null, level=null, likeNumber=89, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/05/25/aee510ed68ce4736e9fe4ec7d03c01b1.jpg, createdBy=ce892064652, createdName=楠博One, createdTime=Mon Jul 17 14:34:19 CST 2017, time=2017-07-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=223230, encodeId=24fb2232308e, content=谢谢分享,学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=102, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo6Nx0VGA4QMDzOP8oAgnV4h51EjSfehJ9QxyiaSmw8PB56BhY8KXFSxHCibXrzcy4abrzSibXQPxJ9kzrLcJyhhB8a/0, createdBy=1d3b1672603, createdName=明月清辉, createdTime=Mon Jul 17 14:14:56 CST 2017, time=2017-07-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=223206, encodeId=27c222320690, content=学习了,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=115, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=550d2008262, createdName=luominglian113, createdTime=Mon Jul 17 12:58:53 CST 2017, time=2017-07-17, status=1, ipAttribution=)]
    2017-07-17 楠博One

    中医博大精深

    0

  6. [GetPortalCommentsPageByObjectIdResponse(id=1811277, encodeId=91aa18112e7ee, content=<a href='/topic/show?id=f0638e57816' target=_blank style='color:#2F92EE;'>#药引子#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87578, encryptionId=f0638e57816, topicName=药引子)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=951d2500061, createdName=12498717m66(暂无昵称), createdTime=Wed Jun 06 18:24:00 CST 2018, time=2018-06-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=224752, encodeId=ef22224e5239, content=不错的文章不错的文章, beContent=null, objectType=article, channel=null, level=null, likeNumber=96, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=eff51996281, createdName=1e1b8538m79(暂无匿称), createdTime=Fri Jul 21 21:27:23 CST 2017, time=2017-07-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1319290, encodeId=f7c71319290ae, content=<a href='/topic/show?id=60172686668' target=_blank style='color:#2F92EE;'>#依从性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=26866, encryptionId=60172686668, topicName=依从性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c9df476, createdName=fyxzlh, createdTime=Wed Jul 19 03:24:00 CST 2017, time=2017-07-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1408991, encodeId=6fa4140899112, content=<a href='/topic/show?id=2c1c35262a9' target=_blank style='color:#2F92EE;'>#医药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=35262, encryptionId=2c1c35262a9, topicName=医药)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=36f62754598, createdName=cathymary, createdTime=Wed Jul 19 03:24:00 CST 2017, time=2017-07-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=223235, encodeId=aa092232352d, content=中医博大精深, beContent=null, objectType=article, channel=null, level=null, likeNumber=89, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/05/25/aee510ed68ce4736e9fe4ec7d03c01b1.jpg, createdBy=ce892064652, createdName=楠博One, createdTime=Mon Jul 17 14:34:19 CST 2017, time=2017-07-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=223230, encodeId=24fb2232308e, content=谢谢分享,学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=102, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo6Nx0VGA4QMDzOP8oAgnV4h51EjSfehJ9QxyiaSmw8PB56BhY8KXFSxHCibXrzcy4abrzSibXQPxJ9kzrLcJyhhB8a/0, createdBy=1d3b1672603, createdName=明月清辉, createdTime=Mon Jul 17 14:14:56 CST 2017, time=2017-07-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=223206, encodeId=27c222320690, content=学习了,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=115, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=550d2008262, createdName=luominglian113, createdTime=Mon Jul 17 12:58:53 CST 2017, time=2017-07-17, status=1, ipAttribution=)]
    2017-07-17 明月清辉

    谢谢分享,学习了

    0

  7. [GetPortalCommentsPageByObjectIdResponse(id=1811277, encodeId=91aa18112e7ee, content=<a href='/topic/show?id=f0638e57816' target=_blank style='color:#2F92EE;'>#药引子#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87578, encryptionId=f0638e57816, topicName=药引子)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=951d2500061, createdName=12498717m66(暂无昵称), createdTime=Wed Jun 06 18:24:00 CST 2018, time=2018-06-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=224752, encodeId=ef22224e5239, content=不错的文章不错的文章, beContent=null, objectType=article, channel=null, level=null, likeNumber=96, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=eff51996281, createdName=1e1b8538m79(暂无匿称), createdTime=Fri Jul 21 21:27:23 CST 2017, time=2017-07-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1319290, encodeId=f7c71319290ae, content=<a href='/topic/show?id=60172686668' target=_blank style='color:#2F92EE;'>#依从性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=26866, encryptionId=60172686668, topicName=依从性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c9df476, createdName=fyxzlh, createdTime=Wed Jul 19 03:24:00 CST 2017, time=2017-07-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1408991, encodeId=6fa4140899112, content=<a href='/topic/show?id=2c1c35262a9' target=_blank style='color:#2F92EE;'>#医药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=35262, encryptionId=2c1c35262a9, topicName=医药)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=36f62754598, createdName=cathymary, createdTime=Wed Jul 19 03:24:00 CST 2017, time=2017-07-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=223235, encodeId=aa092232352d, content=中医博大精深, beContent=null, objectType=article, channel=null, level=null, likeNumber=89, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/05/25/aee510ed68ce4736e9fe4ec7d03c01b1.jpg, createdBy=ce892064652, createdName=楠博One, createdTime=Mon Jul 17 14:34:19 CST 2017, time=2017-07-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=223230, encodeId=24fb2232308e, content=谢谢分享,学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=102, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo6Nx0VGA4QMDzOP8oAgnV4h51EjSfehJ9QxyiaSmw8PB56BhY8KXFSxHCibXrzcy4abrzSibXQPxJ9kzrLcJyhhB8a/0, createdBy=1d3b1672603, createdName=明月清辉, createdTime=Mon Jul 17 14:14:56 CST 2017, time=2017-07-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=223206, encodeId=27c222320690, content=学习了,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=115, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=550d2008262, createdName=luominglian113, createdTime=Mon Jul 17 12:58:53 CST 2017, time=2017-07-17, status=1, ipAttribution=)]
    2017-07-17 luominglian113

    学习了,谢谢分享

    0

相关资讯

中医文化“大咖”谈:中医文化“唤醒”记

导语新华社推出“中医文化‘大咖’谈”大型全媒体融合报道,集中播发一批文字、图片、音视频和网络及新媒体稿件,分别从“中医·唤醒”“中医·健”“中医·艺”“中医·传承”四大方向,全面展示中医药文化的独特魅力,助推中医药现代化,助力中医药走向世界。歧黄之术,华夏瑰宝。自神农氏尝百草,而“内经”,而“伤寒”,而“千金”,而“本草”,源“天人合一”之理、创“望闻问切”之法、集药草针石之功、修“辨证施治”之术

老人延寿新方法 沈阳启动“中医1.2.6三级医养模式”

“中医1.2.6三级医养模式”全国示范区项目在沈阳市正式启动,预计其能让老年人少得病乃至不得病,预计平均延长寿命5至10岁。

洋徒弟杠上老中医:一个难并快乐 一个有了危机感

  图为在云南省中医医院见习的外国中医师学习推拿。 刘冉阳 摄暑假伊始,云南省中医医院的“洋面孔”就多了起来。10日,在推拿诊室,西班牙见习生Idaira已经习惯了病人多瞅两眼式“特别关注”。Idaira是来自西班牙的一名中医医师,其受欧洲中医基金会资助,正在云南省中医医院进行为期三周的进修。“‘老中医’和‘洋徒弟’,只是面孔不一样而已。”Idaira如此回应病人的“特别关注”,但也打趣,“自己第

Chin Med:饮食模式的中医属性与乳腺癌发病率之间的关系

俗话说:"三分治,七分养",饮食就是其中一个内容。自古以来,我国劳动人民就十分重视饮食对人体健康的利害关系,把饮食命为人的命脉,还把饮食当作预防和治疗疾病的一个重要手段。这项回顾性横断面研究旨在探讨中国香港的妇女中乳腺癌的发病率与中医(CM)认为的饮食模式(热性、平和和寒性)之间的关联。研究共纳入了202例乳腺癌患者和202例健康妇女作为对照组,将她们根据人口统计学进行匹配。这些居住在香港法女性在

胃脘痛中医诊疗专家共识意见(2017)

胃脘痛是中医内科最常见的病证之一,临床中多种上消化道疾病均可见胃脘痛症状,如消化性溃疡、慢性胃炎、功能性消化不良等。 中华中医药学会脾胃病分会于于2016 年9 月在北京召开了本共识的最后专家定稿会议完成了本共识意见的制定。

三伏天如何起居饮食,中医支招“体质调养三原则”

近日,上海连日发布高温橙色预警,7月12日起正式进入了“三伏天”,“三伏”是一年中最热的日子,民间百姓说的“苦夏”就在此时。此时气候闷热潮湿,最易诱发各种夏季疾病。三伏天,如何进行饮食、起居调养,安度“苦夏”?今天为大家送上一份中医锦囊。起居:每日温水澡三伏天养生,避暑是总的原则,夏季作息,宜晚些入睡,早些起床。安排劳动或体育锻炼时,要避开烈日炽热之时,并注意加强防护。午饭后,需安排午睡。一则避炎

Baidu
map
Baidu
map
Baidu
map